西妥昔单抗治疗胃肠道恶性肿瘤的临床疗效观察

The clinical efficacy of Cetuximab in treating gastrointestinal malignant tumor

目的探讨分子靶向药重组人源化单克隆抗体西妥昔单抗联合化疗治疗老年胃、肠癌患者的临床疗效及其产生抗癌作用的机制。方法将我院收治的82例胃、肠癌老年患者随机分为观察组和对照组,每组均为41例。对照组采用以氟尿嘧啶为基础的常规FOLFOX4化疗方案,观察组在此基础上加用重组人源化抗VEGF单克隆抗体西妥昔单抗,观察两组患者临床疗效及不良反应发生情况。结果观察组临床治疗有效率为60.9%,临床症状控制率为90.2%,癌细胞凋亡率为27.3±2.83%,对照组临床治疗有效率为34.1%,临床症状控制率为68.2%,癌细胞凋亡率为25.4±2.67%,两组患者以上指标差异有统计学意义(P<0.05);两组间的毒副反应发生率差异无统计学意义(P>0.05)。结论分子靶向药物重组人源化单克隆抗体西妥昔单抗用于治疗恶性肿瘤能取得显著临床疗效和提高患者生活质量,而毒副反应发生率无显著变化。

Objective To explore the clinical efficacy of avastin combined with chemotherapy in the treatment of gastrointestinal cancer.Methods 82 elderly patients with gastrointestinal cancer were randomly divided into observation group and control group .There were 41 cases in each group .The control group was given conventional FOLFOX 4 chemotherapy ,while the observation group was given the monoclonal antibody Avastin in the basis of the FOLFOX4 chemotherapy.The clinical efficacy and the incidence of adverse reactions were observed.Results In the observation group,the clinical efficiency was 58.1%,the clinical symptom control rate was 88.4%,the cancer cell apoptosis rate was 27.3 ±2.83%.While in the control group,the clinical efficiency was 58.1%, the clinical symptom control rate was 88.4%, the cancer cell apoptosis rate was 27.3 ±2.83%.There were significant differences between the two groups in the above indicators(P<0.05).However,the incidence of toxic reaction did not show significant difference between the two groups(P>0.05).Conclusion Cetuximab can significantly improve the clinical efficacy in the treatment of gastrointestinal malignant tumors .